We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+38.76%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$170M
AUM Growth
+$48.4M
Cap. Flow
+$4.74M
Cap. Flow %
2.8%
Top 10 Hldgs %
66.82%
Holding
34
New
9
Increased
8
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$4.21M
2
PACB icon
Pacific Biosciences
PACB
+$3.43M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$3.41M
4
CDXS icon
Codexis
CDXS
+$3.08M
5
TSRO
TESARO, Inc.
TSRO
+$2.85M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.1M
2
BLUE
bluebird bio
BLUE
+$4.49M
3
ILMN icon
Illumina
ILMN
+$3.2M
4
KITE
Kite Pharma, Inc.
KITE
+$3.18M
5
CERN
Cerner Corp
CERN
+$3.08M

Sector Composition

Rank Sector Weight
1 Healthcare 88.88%
2 Materials 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
26
DELISTED
bluebird bio
BLUE
$2.32M 1.37%
1,969
-4,400
-69% -$4.49M
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
$1.46M 0.86%
+23,000
New +$1.4M
ADVM
28
DELISTED
Adverum Biotechnologies
ADVM
$1.13M 0.67%
+42,000
New +$1.19M
CRIS icon
29
Curis
CRIS
$10M
$639K 0.38%
+115
New +$639K
GILD icon
30
Gilead Sciences
GILD
$163B
– –
-12,500
Closed -$895K
ILMN icon
31
Illumina
ILMN
$30B
– –
-25,700
Closed -$3.2M
CERN
32
DELISTED
Cerner Corp
CERN
– –
-65,000
Closed -$3.08M
XLRN
33
DELISTED
Acceleron Pharma
XLRN
– –
-45,000
Closed -$1.15M
GNMX
34
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-375,000
Closed -$1.94M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Casdin Capital held 34 positions worth $170M, up 40% from $121M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Casdin Capital's Q1 2017 filing shows 9 new, 8 increased, 9 reduced and 5 closed positions. Its largest new stake was Audentes Therapeutics, Inc: 260,000 shares worth $4.43M. The largest sale was Global Blood Therapeutics, Inc., an estimated $5.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Materials.

  • Casdin Capital's largest Q1 2017 buy was Audentes Therapeutics, Inc: 260,000 shares worth $4.43M.
  • Casdin Capital added most to Epizyme, Inc in Q1 2017, an estimated $2.8M increase.
  • Casdin Capital's biggest Q1 2017 reduction was Global Blood Therapeutics, Inc., cutting an estimated $5.1M.
  • Casdin Capital fully exited Illumina in Q1 2017, selling an estimated $3.2M.
  • Casdin Capital's ten largest holdings make up 67% of its $170M portfolio in Q1 2017.
  • Casdin Capital opened 9 new positions and closed 5 in Q1 2017.
  • Casdin Capital's portfolio value rose 40% quarter-over-quarter to $170M.

Based on Casdin Capital's 13F filing for Q1 2017, filed 15 May 2017.